NNP
BCRX icon

Nachman Norwood & Parrott’s BioCryst Pharmaceuticals BCRX Stock Holding History

Nachman Norwood & Parrott’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$1K – 338
2020
Q3 		$1K Buy
+200
New +$857 ﹤0.01% 1133

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Nachman Norwood & Parrott's BCRX Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2020, closing a stake of 200 shares — an estimated $1K sold.

Nachman Norwood & Parrott first reported a position in BCRX in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 177 funds tracked by Wall St. Rank hold BCRX as of Q4 2020.

  • Nachman Norwood & Parrott reported no remaining BioCryst Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Nachman Norwood & Parrott sold 200 BioCryst Pharmaceuticals shares in Q4 2020, an estimated $1K.
  • Nachman Norwood & Parrott first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Nachman Norwood & Parrott's BioCryst Pharmaceuticals position peaked at $1K in Q3 2020.
  • 177 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.